Study guide
2.3 Acute Reperfusion Strategies & Nursing Management
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
2.3 Acute Reperfusion Strategies & Nursing Management
Key Takeaways Explain This Topic AI
Primary PCI is the gold-standard reperfusion strategy for STEMI, with strict quality metrics demanding First Medical Contact (FMC) to PCI device time <90 minutes at PCI-capable centers, or <120 minutes if inter-facility transfer is required.
Fibrinolytic therapy is indicated within 12 hours of STEMI symptom onset when primary PCI cannot be performed within 120 minutes, adhering to a Door-to-Needle time <30 minutes while strictly screening for absolute bleeding contraindications.
Dual Antiplatelet Therapy (DAPT) combining non-enteric aspirin with a potent P2Y₁₂ inhibitor (ticagrelor or prasugrel) is loaded immediately to prevent acute stent thrombosis and coronary re-occlusion.
Post-PCI sheath care demands vigilant monitoring for retroperitoneal hematoma—presenting as flank pain, back pain, and sudden unexplained hypotension—as well as pseudoaneurysms and contrast-induced acute kidney injury.
Last updated: August 2026
Primary PCI vs. Fibrinolytic Decision Pathways
In acute STEMI, "time is muscle." Myocardial necrosis begins within 20 minutes of complete coronary occlusion and reaches maximum transmural extent within 6 hours. Emergency reperfusion therapy is mandatory for all patients presenting within 12 hours of symptom onset with clinical STEMI.
Reperfusion Strategy Timelines & Benchmarks
Primary Percutaneous Coronary Intervention (PCI): Primary PCI (balloon angioplasty, aspiration thrombectomy, and stenting) is the preferred reperfusion modality. It achieves superior vessel patency (TIMI 3 flow in >90% of cases), lower rates of re-infarction, and avoids intracranial hemorrhage risks compared to fibrinolysis.
PCI-Capable Facility: First Medical Contact (FMC) to PCI device time must be ≤ 90 minutes .
Non-PCI Facility (Transfer): If a patient presents to a non-PCI facility, emergency transfer to a PCI center is required if FMC-to-device time can be achieved within ≤ 120 minutes . If the expected delay exceeds 120 minutes, immediate fibrinolytic therapy must be administered.
Fibrinolytic Therapy: Indicated for STEMI presenting within 12 hours of symptom onset when primary PCI cannot be delivered within 120 minutes of FMC.
Door-to-Needle Benchmark: Fibrinolytic administration must occur within ≤ 30 minutes of emergency department arrival.
Agents: Fibrin-specific agents are preferred: Tenecteplase (TNK-tPA, administered as a single IV weight-based bolus over 5 seconds), Reteplase (rPA), or Alteplase (tPA).
Pharmacoinvasive Strategy: Following fibrinolysis, all patients should be transferred to a PCI center. If fibrinolysis fails (indicated by <50% resolution of ST elevation at 60-90 minutes post-bolus), emergency rescue PCI is performed immediately. If fibrinolysis is successful, routine angiography is performed within 2 to 24 hours. STEMI Patient Presentation (Symptoms <12 hours)
│
├──> Primary PCI Available within 120 min FMC?
- │ ├──> YES: Primary PCI (Target FMC-to-Device <90 min if direct, <120 min if transfer)
- │ └──> NO: Fibrinolytic Therapy (Target Door-to-Needle <30 min)
- │ │
- │ ├──> Assess ST Resolution at 60-90 min
- │ │ ├──> Failed (<50% resolution): Rescue PCI Immediately
- │ │ └──> Successful (≥50% resolution): Routine Angiography in 2-24 hours
- Absolute Contraindications to Fibrinolytic Therapy
Nurses must immediately screen STEMI candidates for absolute contraindications before administering fibrinolytic agents:
Any prior history of intracranial hemorrhage (ICH).
Known structural cerebrovascular lesion (e.g., arteriovenous malformation).
Known malignant intracranial neoplasm (primary or metastatic).
Ischemic stroke within the preceding 3 months (excluding acute ischemic stroke within 4.5 hours).
Suspected aortic dissection.
Active bleeding or bleeding diathesis (excluding menses).
Significant closed-head or facial trauma within the preceding 3 months.
Intracranial or intraspinal surgery within 2 months.
Severe uncontrolled hypertension unresponsive to emergency therapy (systolic BP >180 mmHg or diastolic BP >110 mmHg).
Loading diagram... STEMI Reperfusion Decision Algorithm and Timelines
Antithrombotic & Antiplatelet Pharmacotherapy
Secondary prevention of stent thrombosis and propagation of coronary thrombi requires potent combination antithrombotic therapy.
Dual Antiplatelet Therapy (DAPT)
DAPT combines Aspirin with an oral P2Y₁₂ receptor inhibitor:
Aspirin: Loaded immediately with 162 to 325 mg non-enteric coated chewable aspirin, followed by 81 mg daily indefinitely.
P2Y₁₂ Inhibitors:
Ticagrelor (Brilinta): Loaded with 180 mg , followed by 90 mg BID. Direct, reversible P2Y₁₂ inhibitor. Preferred over clopidogrel due to superior mortality reduction.
Prasugrel (Effient): Loaded with 60 mg , followed by 10 mg daily. Irreversible P2Y₁₂ inhibitor. Absolute Contraindication: Prior history of stroke or Transient Ischemic Attack (TIA) due to severe risk of intracranial bleeding.
Clopidogrel (Plavix): Loaded with 300 to 600 mg , followed by 75 mg daily. Prodrug requiring hepatic CYP2C19 cleavage. Reserved for cases where ticagrelor/prasugrel are unavailable or contraindicated.
Parenteral Anticoagulation
Parenteral anticoagulants are administered during PCI and maintained in NSTEMI/UA:
Unfractionated Heparin (UFH): IV bolus (70-100 units/kg) to maintain target Activated Clotting Time (ACT) 250-300 seconds during PCI (or aPTT 50-70 seconds post-PCI).
Bivalirudin (Angiomax): Direct thrombin inhibitor. Associated with significantly lower rates of major bleeding compared to heparin plus GP IIb/IIIa inhibitors in high-bleeding-risk PCI.
Enoxaparin (LMWH): Preferred parenteral anticoagulant in NSTEMI managed medically.
Glycoprotein IIb/IIIa Inhibitors
Agents such as Eptifibatide (Integrilin) and Tirofiban (Aggrastat) block the final common pathway of platelet aggregation. They are utilized as bailout therapy in the catheterization laboratory during PCI for heavy intra-coronary thrombus burden, no-reflow phenomenon, or acute intra-procedural thrombotic complications.
Post-PCI Vascular Access Sheath Care & Complication Management
Vascular access for PCI is achieved via the radial or femoral artery. Nurses manage post-procedural hemostasis and rapidly identify access site complications.
Femoral Access Sheath Removal & Care
Pre-removal Checks: Verify coagulation parameters: Activated Clotting Time (ACT) must be <150-180 seconds (or aPTT <45 seconds) prior to manual sheath pull.
Manual Pull Technique: Apply direct manual compression 1 to 2 cm proximal to the skin puncture site (the arteriotomy site is located superior to the skin nick) for 20 to 30 minutes. Maintain bed rest flat (head of bed ≤ 30^°) with the affected leg immobilized for 4 to 6 hours.
Vascular Closure Devices (VCDs): Devices like Angio-Seal (collagen plug) or Perclose (suture-mediated) reduce bed rest times to 2 hours.
Radial Access & Compression Devices
Radial artery access is now preferred due to dramatically lower vascular bleeding complications. A radial compression device (TR Band) is applied. Air is sequentially deflated per protocol over 2 to 4 hours while assessing for radial artery patency (using the Barbeau test) and absence of hematoma.
Major Access Site Complications
Retroperitoneal Hematoma (RPH): A rare but life-threatening complication resulting from a high femoral arterial puncture (above the inferior epigastric artery or inguinal ligament), allowing uncontained bleeding into the retroperitoneal space.
Clinical Presentation: Unexplained sudden back pain, flank pain, ipsilateral groin pain, combined with sudden refractory hypotension, tachycardia, and a dropping hemoglobin/hematocrit.
Diagnostic Choice: Non-contrast CT scan of the abdomen and pelvis.
Nursing Interventions: Immediately apply firm manual pressure over the femoral site, administer rapid IV fluid boluses and blood products, reverse active anticoagulation (protamine for heparin), and notify vascular surgery.
Pseudoaneurysm: Disruption of arterial wall layers resulting in a pulsating hematoma encapsulated by fibrous tissue, maintaining communication with the arterial lumen.
Presentation: A painful, pulsatile mass at the groin access site with an audible bruit on auscultation.
Confirmation & Management: Confirmed via duplex ultrasound. Small pseudoaneurysms (<2 cm) are monitored; larger ones are treated with ultrasound-guided thrombin injection or surgical repair.
Contrast-Induced Acute Kidney Injury (CI-AKI): An absolute rise in serum creatinine ≥ 0.5 mg/dL or ≥ 25% baseline increase within 48 to 72 hours post-contrast administration.
Prevention Protocol: Aggressive isotonic IV normal saline hydration (1.0-1.5 mL/kg/h for 12 hours pre- and post-PCI), minimization of contrast volume, and holding nephrotoxic medications (NSAIDs, ACE inhibitors, ARBs).